Form 4: Soleno CFO Granted Equity Awards

Soleno Therapeutics' Chief Financial Officer, James H. Mackaness, received grants of restricted stock units and employee stock options.

Summary

• James H. Mackaness, Chief Financial Officer of Soleno Therapeutics Inc. (SLNO), was granted equity awards on January 21, 2026.
• He received 28,600 Restricted Stock Units (RSUs), which represent a contingent right to receive one share of Common Stock each.
• These RSUs are scheduled to vest 100% on December 15, 2027, contingent on his continued service.
• Additionally, he was granted 32,800 employee stock options with an exercise price of $43.65 per share.
• The stock options will vest in monthly increments, with 1/48th of the shares vesting on February 1, 2026, and each subsequent one-month anniversary, also subject to continued service.
• Following these transactions, Mackaness beneficially owns 131,763 non-derivative securities and 32,800 derivative securities (options).

Sentiment

Score: 7

Explanation: The filing reports routine executive compensation, which is generally positive for aligning management and shareholder interests, but does not contain news that would significantly alter the company's fundamental outlook or financial performance.

Positives

• The grant of equity awards aligns the Chief Financial Officer's long-term interests with those of the shareholders, incentivizing company performance.
• The multi-year vesting schedules for both RSUs and stock options promote executive retention and commitment to the company's future success.

Future Outlook

The grants of equity awards with future vesting dates indicate a long-term commitment to the company's performance and executive retention, suggesting management's confidence in future value creation.

Industry Context

Equity grants, including Restricted Stock Units and stock options with multi-year vesting, are a standard practice in the biotechnology and pharmaceutical industry. This compensation structure is widely used to incentivize and retain key executives, aligning their financial interests with the long-term growth and shareholder value creation of the company. The specific terms reflect Soleno Therapeutics' compensation strategy within this competitive sector.

Comparison to Industry Standards

• The use of RSUs and stock options with multi-year vesting schedules is a common compensation structure for executives in the biotech sector, comparable to practices at companies like BioNTech or Moderna, aiming to tie executive performance to long-term company success and share price appreciation.
• The specific number of units and the option exercise price would typically be benchmarked against peer companies of similar market capitalization, stage of development, and therapeutic focus to assess the competitiveness and appropriateness of the compensation package.

Stakeholder Impact

• Shareholders: The equity grants are designed to align the CFO's financial incentives with long-term shareholder value creation. However, the future exercise of options and vesting of RSUs will lead to some share dilution.
• Employees: The executive compensation structure may influence overall company compensation philosophy and morale, though this filing specifically pertains to a senior officer.

Next Steps

• Continued monthly vesting of 1/48th of the employee stock options, commencing February 1, 2026.
• Full vesting of the 28,600 Restricted Stock Units on December 15, 2027, subject to continued service.

Key Dates

Keywords

Soleno Therapeutics, SLNO, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Executive Compensation, CFO